The convergence of pharmacogenomics and cannabis therapeutics has entered a critical phase with the emergence of THCa vaporization as a delivery method requiring genetically-informed clinical protocols. Budpop’s THCa vape and similar products represent a rapidly expanding market where individual genetic variation significantly impacts therapeutic outcomes, safety profiles, and dosing requirements—yet clinical implementation remains hampered by limited integration of genomic screening. Understanding how cytochrome P450 polymorphisms, particularly CYP2C9 and CYP3A4 variants, modulate THCa …
